# RenaMed Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/renamed-biologics

- Industry: Biotechnology
- Headquarters: Lincoln, US
- Total disclosed funding: $27M
- Latest round: Series E (Sep 7, 2006)
- Investors on record: 13

## About

RenaMed Biologics a biotechnology company, engages in the development and commercialization of therapies for the treatment of diseases associated with compromised kidney function.

## Funding rounds

- Series E, Sep 7, 2006, $27M — Northcoast Capital Management, TVM Capital Life Science, Seaflower Ventures, Apjohn Ventures, CDPQ, BD Ventures, DFJ Portage Venture Partners, SG Growth Capital, Sanofi Ventures, Lurie Investments, Merlin BioMed Group, TSC BioVenture Management, Lumira Ventures

## Investors

- Northcoast Capital Management (https://capitalatlas.ai/funds/northcoast-capital-management) — Series E
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series E
- Seaflower Ventures (https://capitalatlas.ai/funds/seaflower-ventures) — Series E
- Apjohn Ventures (https://capitalatlas.ai/funds/apjohn-ventures) — Series E
- CDPQ — Series E
- BD Ventures (https://capitalatlas.ai/funds/bd-ventures) — Series E
- DFJ Portage Venture Partners (https://capitalatlas.ai/funds/dfj-portage-venture-partners) — Series E
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series E
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series E
- Lurie Investments — Series E
- Merlin BioMed Group — Series E
- TSC BioVenture Management — Series E
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series E